Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients

Transplantation. 2009 Oct 15;88(7):891-6. doi: 10.1097/TP.0b013e3181b6f38c.


Background: Despite the prevalent use of rabbit antithymocyte globulin (rATG) as an induction agent in kidney transplantation, the appropriate dose for preventing acute rejection in high-risk patients is not known. Few studies have examined total exposure of rATG less than 6 mg/kg, with fewer studies examining lower dose rATG in patients with increased risk factors for acute rejection.

Methods: We retrospectively analyzed outcomes of 83 kidney transplant recipients at increased risk for acute rejection (repeat transplant, African American race, and panel reactive antibody > or =20%) from July 2004 to July 2007 who were treated with rATG 1.5 mg/kg per day for 3 (n=39) or 4 (n=44) doses for induction to determine the impact of reduced-exposure rATG in the prevention of acute rejection. rATG was initiated intraoperatively and continued on consecutive days. All patients received triple maintenance immunosuppression including prednisone and calcineurin inhibitor. Patients requiring dialysis within 48 hr after transplant were excluded from analysis.

Results: One-year acute rejection rates were 10% and 11% in the 3- and 4-dose cohorts, respectively, with 100% patient and graft survival at 1 year in both groups. Patients in the 3-dose cohort were discharged from the hospital sooner than the 4-dose cohort (median length of hospital stay, 3 vs. 4 days; P=0.004).

Conclusions: Our results suggest that a 3- or 4-dose course of rATG (1.5 mg/kg/dose) provides excellent protection against acute rejection even in patients at increased risk, with the potential for cost savings from a reduction in hospital stay and medication administration.

MeSH terms

  • Animals
  • Antilymphocyte Serum / therapeutic use*
  • Dose-Response Relationship, Drug
  • Follow-Up Studies
  • Graft Rejection / prevention & control*
  • Graft Survival / drug effects
  • HLA-D Antigens / immunology
  • Histocompatibility Antigens Class I / immunology
  • Immunosuppressive Agents / therapeutic use
  • Isoantibodies / blood
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality
  • Patient Discharge
  • Patient Selection
  • Rabbits
  • Reoperation / statistics & numerical data
  • Retrospective Studies
  • Risk
  • Survival Rate
  • Survivors
  • Time Factors


  • Antilymphocyte Serum
  • HLA-D Antigens
  • Histocompatibility Antigens Class I
  • Immunosuppressive Agents
  • Isoantibodies